Direct ELISA method for the specific determination of prothymosin alpha in human specimens

Area of Science:

• Biochemistry
• Immunology
• Oncology

Background:

• Prothymosin alpha (ProT alpha) is a protein with various biological functions.
• Accurate quantification of ProT alpha is essential for understanding its role in health and disease.
• Existing methods may lack specificity or require sample pretreatment.

Purpose of the Study:

• To develop a highly specific and sensitive enzyme-linked immunosorbent assay (ELISA) for prothymosin alpha (ProT alpha).
• To validate the ELISA's ability to discriminate ProT alpha from related peptides.
• To measure ProT alpha levels in human serum and breast tissue samples.

Main Methods:

• Developed a ProT alpha-specific ELISA using a C-terminal peptide antibody and bovine ProT alpha standards.
• Validated antibody specificity against parathymosin alpha (ParaT alpha) and thymosin alpha1 (T alpha1).
• Directly quantified ProT alpha in human serum and breast tissue extracts without pretreatment.

Main Results:

• The developed ELISA demonstrated high specificity, distinguishing ProT alpha from ParaT alpha and T alpha1.
• ProT alpha was directly quantifiable in human serum and tissue extracts.
• Mean ProT alpha levels were lower in breast cancer patients (1.02 +/- 0.29 microg/ml) compared to healthy individuals (1.27 +/- 0.49 microg/ml).
• ProT alpha levels were elevated in breast tumor tissue extracts compared to adjacent normal tissue.

Conclusions:

• A novel, specific, and sensitive ELISA for ProT alpha has been successfully developed.
• The assay enables direct measurement of ProT alpha in biological samples.
• Findings suggest altered ProT alpha levels in breast cancer patients and tumor tissues, warranting further investigation.